Search This Blog

Tuesday, August 9, 2022

Halozyme Financial Report and Business Update

 Closed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022

Second Quarter Revenue Increased 12% YOY to $152.4 million, with GAAP Diluted Earnings per Share of $0.16 and Non-GAAP Diluted Earnings per Share of $0.53

Record Second Quarter Royalty Revenue Increased 86% YOY to $85.3 million

Raising 2022 Revenue Guidance to $655 Million to $685 Million, up from $530 Million to $560 Million, Representing 48%-55% Growth over Reported 2021 Revenue     

https://finance.yahoo.com/news/halozyme-reports-second-quarter-2022-200100443.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.